liposomal irinotecan Onivyde
Selected indexed studies
- Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs. (Cancer Sci, 2022) [PMID:35445479]
- NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. (Eur J Cancer, 2019) [PMID:30654298]
- Fluorescence Lifetime Nanoscopy of Liposomal Irinotecan Onivyde: From Manufacturing to Intracellular Processing. (ACS Appl Bio Mater, 2023) [PMID:37699572]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs. (2022) pubmed
- Irinotecan-Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview. (2020) pubmed
- NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. (2019) pubmed
- Fluorescence Lifetime Nanoscopy of Liposomal Irinotecan Onivyde: From Manufacturing to Intracellular Processing. (2023) pubmed
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. (2016) pubmed
- A phase I study of liposomal Irinotecan (ONIVYDE®) in combination with TAS-102 (LONSURF®) in refractory solid tumors. (2025) pubmed
- Consensus, debate, and prospective on pancreatic cancer treatments. (2024) pubmed
- NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis. (2024) pubmed
- Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer: The Phase 2b NIFTY Randomized Clinical Trial. (2023) pubmed
- Targeting Topoisomerase I in the Era of Precision Medicine. (2019) pubmed